Compare DHX & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | TTRX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.3M | 281.2M |
| IPO Year | 2007 | N/A |
| Metric | DHX | TTRX |
|---|---|---|
| Price | $3.84 | $8.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.25 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 125.3K | 124.9K |
| Earning Date | 05-05-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $127,826,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $94.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $2.57 |
| 52 Week High | $4.33 | $11.69 |
| Indicator | DHX | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 55.17 |
| Support Level | $3.58 | $8.51 |
| Resistance Level | $4.00 | $11.69 |
| Average True Range (ATR) | 0.27 | 1.12 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 20.37 | 27.11 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.